Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
DataMeds AI, Inc. is registering 34,462,058 shares of common stock for resale by existing selling stockholders. The shares consist of previously issued stock, shares issuable from May 2026 convertible notes and related Series A preferred stock, and shares underlying PIPE and placement agent warrants. The company itself is not selling stock and will receive no proceeds from these resales, only potential cash from any future PIPE or placement agent warrant exercises.
These financings use variable conversion prices, floors as low as $1.00 per share, and Series A preferred stock with a 10% annual dividend added to stated value, which can substantially increase shares issued over time. With 2,847,198 shares outstanding as of July 27, 2026, the company estimates up to 36,027,113 shares could be outstanding if all May 2026 notes convert at $1.00 and all PIPE and placement agent warrants are exercised, implying significant dilution. DataMeds operates a micro health ecosystem combining wholesale distribution, a technology hub platform and a multi‑state pharmacy. It recently completed a 1‑for‑50 reverse split to regain Nasdaq’s $1.00 bid requirement and is working to restore compliance with Nasdaq’s $2.5 million stockholders’ equity standard by October 12, 2026.
DataMEDS AI, Inc. entered into an Amended and Restated Letter of Intent with EOS Technology Holdings, Scilex Holding Company, Datavault AI Inc., and HealthBridge Advisors to negotiate a stock-based transaction. The contemplated deal would acquire or exclusively license QOLPOM/QLPM intellectual property from EOS and Scilex, expand the existing PharmacyChain license to include Datavault AI Health, and obtain a controlling interest in Tollo Health, LLC through an exchange of membership interests with HealthBridge Advisors.
The parties expect new investors and partners to hold approximately 84.6% of common stock on a fully diluted, post-closing basis, with Fortitude Advisors at about 5% and existing public stockholders at about 10.4%, subject to detailed capitalization modeling and multiple adjustments. The LOI includes liability reduction and financing frameworks, six‑month post-closing lock-ups for certain holders, and a registration rights agreement requiring resale registration of Acquisition Stock within 45 days of closing. Closing remains subject to due diligence, definitive agreements, a fairness opinion, corporate and stockholder approvals, financing, Nasdaq requirements (including potential change-of-control treatment), and other customary conditions, and there is no assurance the transaction will be completed.
DataMeds AI, Inc. updated the record date for its planned distribution of the Dream Bowl 2026 Meme Coin to stockholders to August 7, 2026. Holders of common stock on that date are entitled to receive 50 DREAM coins per share, compared with the previously announced distribution of one coin per share.
The distribution date will be set later in coordination with DataVault AI. As of this announcement, the company has 2,847,198 common shares outstanding; about 1,533,930 shares are subject to 90‑day lock-up agreements, while 919,465 shares are held at DTCC and available for trading. DataMeds also reports 80,826 outstanding cash warrants with a $35.00 exercise price and no currently convertible debt or preferred equity.
Wellgistics Health, Inc. has amended its Delaware charter to change its corporate name to DataMeds AI, Inc., effective July 22, 2026. On the same date, its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol MEDS, replacing WGRX.
The company states that the name and symbol changes do not alter stockholder rights or require any stockholder action. Management frames the rebranding around an AI-driven digital health strategy integrating its EinsteinRx and PharmacyChain platforms with the Health Lives Here app and other telemedicine and data-management offerings.
Wellgistics Health director Surendra K. Ajjarapu exercised warrants to acquire 100,000 shares of Common Stock at $0.005 per share on June 22, 2026. The warrants had been issued on March 31, 2026 in lieu of cash compensation. Following the issuer’s reverse stock split effective May 26, 2026 and this warrant conversion, Ajjarapu directly holds 257,645 shares of Common Stock, and the exercised warrant position is reduced to zero.
Wellgistics Health, Inc. Chief Executive Officer Prashant Patel exercised compensation-related warrants into common stock. On June 22, 2026, he exercised warrants covering 100,000 shares of common stock at an exercise price of $0.005 per share, converting them into common shares.
The warrants were originally issued to him on March 31, 2026 in lieu of cash compensation. Following a reverse stock split effective May 26, 2026 and this warrant conversion, Patel now directly holds a total of 282,365 shares of Wellgistics common stock.
Wellgistics Health, Inc. reported that Chief Executive Officer Prashant Patel received a large equity compensation package. On March 31, 2026, he was granted 5,000,000 shares of common stock at an indicated value of $0.20 per share, bringing his direct holdings to 9,118,247 common shares after the award. On the same date, he also received 5,000,000 warrants to purchase common stock with an exercise price of $0.0001 per share, exercisable from March 31, 2026 and expiring on March 31, 2031. Both the shares and the warrants were issued as compensation for his service and were granted in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Wellgistics Health, Inc. director Surendra K. Ajjarapu received a large equity compensation package. On March 31, he was granted 5,000,000 shares of common stock at $0.20 per share as compensation for his service, bringing his direct holdings to 7,882,247 shares.
He was also granted 5,000,000 warrants to purchase common stock with a $0.0001 exercise price, exercisable from March 31 and expiring on March 31, 2031. Both the shares and warrants were issued as compensation in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Wellgistics Health, Inc. is soliciting proxies for its virtual Annual Meeting on July 20, 2026 to seek stockholder approval of six proposals, including a corporate name change to DataMeds AI, Inc., authorization of 1,000,000 shares of blank‑check preferred stock, amendments to its equity incentive plan and related issuance of 6,000 shares of super‑voting preferred stock, election of five directors, and ratification of its independent auditor.
The proxy statement discloses governance and compensation details including stockholder record date of June 22, 2026 with 2,647,198 shares outstanding, key executive employment and equity awards (notably a 9,000,000 RSU grant to a former CEO and multi‑million dollar grant values to current executives), committee composition, and beneficial ownership tables. The Board recommends a vote FOR each proposal.
Wellgistics Health, Inc. received an extension from Nasdaq to regain compliance with the stockholders’ equity listing standard after previously reporting stockholders’ equity of $(12,447,801) as of December 31, 2025, below the $2,500,000 minimum. The company is pursuing transactions with DataVault AI and Tollo Health and estimates a potential combined asset value of $4 billion and post-transaction stockholders’ equity of about $40 million.
Nasdaq’s letter allows Wellgistics until October 12, 2026 to demonstrate equity compliance through one of two reporting alternatives that include detailed disclosure and, if used, a pro forma balance sheet evidencing sufficient equity. Separately, Nasdaq confirmed the company has regained compliance with the $1.00 minimum bid price requirement after its common stock closed at or above that level for each business day from May 26, 2026 to June 8, 2026, so that matter is now closed.